

## Remarks

### The Amendments

#### Claims

Claim 3 has been amended to recite dependency from claim 35 in place of claim 8.

Claim 4 has been amended to recite dependency from claim 36 in place of claim 9. Claims 8 and 9 have been canceled as directed to a non-elected invention. Claims 35 and 36 are new independent claims introduced in an examiner's amendment to which claims 3 and 4 properly depend.

Claims 3 and 4 have also been amended to recite that the peptide "is a membrane-penetrating peptide" in place of "is fused to a membrane-penetrating peptide." The amendment more correctly refers to the "polypeptide which provides an additional functional property" recited in claim 35, the claim from which claims 3 and 4 ultimately depend.

Claim 6 has been amended to recite is selected "from" the group consisting of in place of "form" the group consisting of.

Each of these amendments merely addresses a formal matter and does not narrow the scope of the claims. Entry of these amendments is respectfully requested.

#### Specification

The specification has been amended at page 4, lines 7-9 to refer to the sequence identifiers in the substitute sequence listing that are associated with each of the sequences disclosed in Figure 1A.

The specification has also been amended to include a substitute sequence listing. The substitute sequence listing includes new SEQ ID NO:6, which is disclosed as "NEG1" in Figure 1A.

#### Sequence Listing


The Office Action asserts that the application does not comply with the sequence rules under 37 C.F.R. §§ 1.821-1.825 because the sequences disclosed in Figure 1A are not referred to by a sequence identifier. The specification has been amended at the description of Figure 1A to include the sequence identifiers for each of the disclosed sequences.

A substitute sequence listing also accompanies this amendment. The substitute sequence listing includes the sequence disclosed as "NEG1" in Figure 1A. Thus the substitute sequence listing introduces no new matter. A paper and computer readable format copy of the substitute sequence listing accompanies this response. I believe that the paper and computer readable format copies of the substitute sequence listing are identical.

Respectfully submitted,

Date: December 12, 2003

By:

  
Michelle L. Holmes-Son  
Registration No. 47,660

Banner & Witcoff, Ltd.  
1001 G Street, N.W., Eleventh Floor  
Washington, D.C. 20001-4597  
(202) 824-3000